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Abstract 
Review on SPINK1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords: SPINK1 
Identity 
Other names: PSTI, TATI, SPIK 
HGNC (Hugo): SPINK1 
Location: 5q32 
Location (base pair): location 147,204,131-
147,211,349 reverse (minus) strand (Human genome 
assembly GRCh37.p12, Ensembl release 73 - 
September 2013). 
Local order: Several other SPINK genes have been 
mapped in the same chromosomal region. From 
centromere to telomere (Ensembl genome browser 
73): DPYSL3 (reverse strand) - JAKMIP-2 (reverse) 
- SPINK1 (reverse) - SCGB3A2 (forward) - C5orf46 
(reverse) - SPINK5 (forward) - SPINK14 (forward) 
- SPINK6 (forward) - SPINK13 (forward) - SPINK7 
(forward). 
DNA/RNA 
Some other SPINK family members are similar in 
size, are encoded for by 4 exons and contain a  
single Kazal type serine protease inhibitor domain. 
Description 
Maps to chromosomal region 5q32: 147,204,131-
147,211,349 on reverse (minus) strand (7,219 bp). 
Gene consists of 4 exons (Horii et al., 1987). Region 
between 3.8 and 4.0 kb upstream from the translation 
initiation codon contains an interleukin-6 responsive 
element (IL6RE) and two potential AP-1 binding 
sites (Ohmachi et al., 1993; Yasuda et al., 1993). 
CAATCAATAAC sequence (-149 to -139) is a 
potential pancreas-specific regulatory element 
(Yasuda et al., 1998).  
This region in the SPINK1 promoter has been 
subsequently identified as a binding site for hepatic 
nuclear factor (HNF1) (Boulling et al., 2011). A 
putative binding site for pancreas-specific 
transcription factor 1 (PTF1) has also been identified 
within the SPINK1 promoter (Boulling et al., 2011). 
Transcription 
SPINK1 mRNA (NCBI Reference Sequence: 
NM_003122.3) has 454 bp (Yamamoto et al., 1985). 
Expression, at least in some cell lines, is regulated by 
IL-6 (Yasuda et al., 1993). Three differentially 
spliced mRNA forms have been described (Ensembl, 
release 73). Two of these have been classified as 
protein encoding. 
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Chromosomal location and gene structure of SPINK1 gene (extracted from Ensembl database release 73). Some putative 
regulatory elements are also shown (Ohmachi et al., 1993; Yasuda et al., 1993; Yasuda et al., 1998; Boulling et al., 2011). After 
the translation-initiating codon (ATG) exons of the major transcript are shown in black. One splicing variant also contains parts 
outside of these exons. *, CAATCAATAAC, potential pancreas-specific regulatory element; IL6RE, interleukin-6 responsive 
element; AP-1, activator protein-1 element; HNF1, hepatic nuclear factor; PTF1, pancreas-specific transcription factor 1. 
 
Protein 
In the literature, SPINK1 is widely referred to as 
TATI (tumor-associated trypsin inhibitor) and PSTI 
(pancreatic secretory trypsin inhibitor). 
Description 
SPINK1(NCBI Reference Sequence: NP_003113.2 ; 
UniProtKB/Swiss-Prot: ISK1_HUMAN, P00995; 
PDB: 1cgj; 1cgi; 1hpt) is a 6242 Da secreted protein, 
containing 79 amino acids. Mature SPINK1 contains 
56 amino acids and three disulfide bonds. It has a 
Kazal-type serine protease inhibitor domain and 
belongs to the SPINK (serine peptidase inhibitor, 
Kazal-type) family. SPINK1 has been reported to 
inhibit several proteases, including human trypsin-1 
and -2 (cationic and anionic trypsins), acrosin and 
granzyme A (Pubols et al., 1974; Huhtala et al., 
1984; Turpeinen et al., 1988; Tsuzuki et al., 2003). 
Expression 
SPINK1 was first characterized in bovine pancreas 
(Kazal et al. 1948) and pancreatic juice (Greene 
1966), and later from human pancreatic juice (Fritz  
et al 1967). SPINK1 is mainly expressed in the 
pancreas, but to a lesser extent also in several other 
tissues, e.g., in the gastrointestinal tract, including 
the liver, duodenum, small intestine, gall bladder, 
colon, appendix, stomach, and in the genitourinary 
tract, e.g., prostate and urothelium (Paju and 
Stenman, 2006; Itkonen and Stenman, 2014). 
Expression has been found also in kidney, lung, 
breast, brain, spleen and ovary. SPINK1 is often 
strongly expressed in ETS-rearrangement-negative 
prostate cancers (Tomlins et al., 2008). A putative 
bipartite pancreas-specific transcription factor 1 
(PTF1)-binding sequence has been identified 
(Boulling et al., 2011) in the SPINK1 gene. Outside 
the pancreas, SPINK1 has been considered an 
inflammatory pleiotropic cytokine, which is 
regulated by immune and inflammatory responses. 
In some cell lines, the expression is regulated by IL-
6 (Yasuda et al., 1993). In cultured prostate cancer 
cells, SPINK1 expression has been shown to be 
regulated by androgens (Paju et al., 2007). In mouse, 
the synthesis of Spink3 (mouse orthologue of 
SPINK1) is dependent upon testicular androgens in 
the sex accessory tissues, but not in the pancreas 
(Mills et al., 1987).  
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Ribbon diagram of recombinant SPINK1 variant (RSCB Protein Data Bank code 1HPT (Hecht et al., 1991)). Protein Workshop 
program (Moreland et al., 2005) with the surfaces feature (Xu and Zhang, 2009) was used for visualization. Cysteines, forming 
three disulfide bonds, are shown as balls and sticks. The atoms of asparagine-34 (N34) residue, mutation in which is associated 
with chronic pancreatitis, and reactive site lysine (K41) are shown as balls without side-chains. Alpha-helix is shown in blue and 
beta-sheets in yellow. 
 
Very high serum and urine concentrations occur in 
patients with pancreatitis (Ogawa, 1988). Serum 
levels of SPINK1 may also be elevated in several 
cancers, including prostate cancer, ovarian cancer 
and benign cysts, renal-cell carcinoma, bladder 
carcinoma, and colorectal cancer (Paju and Stenman, 
2006; Itkonen and Stenman, 2014). Severe 
inflammation, tissue destruction and major trauma 
leads to an acute phase reaction causing increased 
circulating SPINK1 concentrations. 
Localisation 
SPINK1 is highly expressed in the pancreas (Kazal 
et al., 1948). It has been localized to the zymogen 
granules of pancreatic acinar cells, where it protects 
the pancreas from premature activation of 
trypsinogens. SPINK1 is secreted into the pancreatic 
fluid along with digestive enzymes. Many cancers 
secrete SPINK1 causing elevated serum 
concentrations (Paju and Stenman, 2006; Itkonen 
and Stenman, 2014). 
Function 
SPINK1 is a protease inhibitor and has been reported 
to inhibit human trypsin-1 and -2 (cationic and 
anionic trypsins), but not trypsin-3 
(mesotrypsin)(Sahin-Tóth, 2005). SPINK1 also 
inhibits granzyme A (Tsuzuki et al., 2003), plasmin, 
urokinase, tissue plasminogen activator (Turpeinen 
et al., 1988) and acrosin (Huhtala et al., 1984). 
SPINK1 has been reported to exert growth 
stimulation of cultured cells (Niinobu et al., 1990) 
and to activate the EGF-receptor (Ozaki 2009; Ateeq 
et al., 2011). However, growth stimulation by 
mechanisms other than via EGF receptor cannot  
be ruled out. It has been suggested that SPINK1 
mediates tumor growth, differentiation, and 
angiogenesis via stimulation of the EGF-receptor or 
by suppression of serine-protease- or caspase-
dependent apoptosis (Ateeq et al., 2011; Gouyer et 
al., 2008). There is evidence that SPINK1 plays a 
role in tissue differentiation (Ohmuraya et al., 2005) 
and repair (Marchbank et al., 1996), reproduction 
(Huhtala, 1984) and regulation of apoptosis (Lu et 
al., 2011). Over-expression of SPINK1 in cancer 
could block cancer cell apoptosis resulting in 
suppression of the immune response and escape of 
cancer cells from immune surveillance (Lamontagne 
et al., 2010). 
Homology 
SPINK1 contains a Kazal-type serine protease 
inhibitor domain, found in many other proteins and 
especially in members of SPINK family. Apart from 
this domain, SPINKs do not share high sequence 
similarity. Apart from SPINK5, SPINKs are of 
similar size and most genes contain the same number 
of exons. Some of the family members lack 
functional annotatation. A functional SPINK1 
orthologue, Spink3 (NP_033284.1), has been found 
in mouse. The rat has two orthologues, Spink1 
(NP_690919.1) and Spink3 (NP_036806.1) 
(HomoloGene, Release 67). Orhologues have been 
found also in common chimpanzee 
(XP_001160275.1), rhesus macaque 
(XP_001102888.1), grey wolf (XP_850557.1) and 
cattle (NP_001020519.1). Sequence similarity 
between SPINK1 and EGF has been reported (Hunt 
et al., 1974). 
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Relative mRNA expression levels of SPINK1 in different tissues. The data is from the IST4 database containing gene expression 
data in ~10 000 samples (http://ist.medisapiens.com/) (Kilpinen et al., 2008). 
 
Mutations 
NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) reports 631 
SPINK1 SNPs (Homo sapiens, December 29., 
2014).  
At least 15 missense mutations have been described 
in the mature polypeptide and three in the signal 
peptide (Chen and Férec, 2009). Association of 
mutations with familial pancreatitis and other 
diseases has been described (see below). 
Implicated in 
Liver cancer 
Up-regulation of SPINK1 in tissue has been shown 
to distinguish hepatocellular carcinoma (HCC) from 
benign liver disease and normal liver (Marshall A 
2013). Elevated serum concentrations of SPINK1 
are associated with adverse prognosis of 
hepatocellular cancer (Lyytinen et al., 2013). Serum 
SPINK1 is also a useful marker for distinguishing 
between patients with or without liver metastasis of 
colorectal and breast cancer (Taccone W 1991;  
 
Gaber A 2010). 
Disease 
HCC is the fifth most frequently diagnosed cancer 
and the second most common cause of cancer death 
worldwide in men (Jemal et al., 2011).  
In females the rate is about half of that of men. Half 
of the cases occur in China and liver cancer is less 
common in Western countries.  
HCC is the most common type of liver cancer. It may 
be caused by viral infections, like hepatitis B and C, 
or cirrhosis.  
Most tumors in the liver are not primary liver 
cancers, but metastases of other cancers. 
Prognosis 
Plasma SPINK1 concentration is elevated in HCC 
patients and it correlates with tumor size (Ohmachi 
et al., 1993).  
Overexpression of SPINK1 mRNA is a stage-
independent prognostic factor and a predictor of 
early tumor recurrence in HCC (Lee et al., 2007) and 
in cholangiocarcinoma (Tonouchi et al., 2006). 
Serum SPINK1 has been shown to predict adverse 
prognosis in HCC (Lyytinen I 2013). 
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Prostate cancer 
SPINK1 is often overexpressed in ETS-
rearrangement-negative prostate cancers (Tomlins et 
al., 2008). 
Disease 
Prostate cancer is a considerable health care problem 
with 342 000 new cases and about 71 000 deaths 
annually in the EU countries, it is the most frequently 
diagnosed cancer in men and the third most common 
cause of cancer death (data from GLOBOCAN 
2008).  
Prostate cancer can be diagnosed by screening at an 
early stage, when most patients can be cured by 
radical prostatectomy or radiotherapy.  
However, about one third of the tumors relapse. 
Most of these cases can be treated by androgen 
ablation, but within 3 - 5 years the tumor usually 
becomes castration-resistant. 
Prognosis 
High SPINK1 expression has been associated with 
adverse prognosis in prostate cancer in some 
(Tomlins et al., 2008; Paju et al., 2007), but not all 
studies (Leinonen et al., 2013; Grupp et al., 2013; 
Lippolis et al., 2013).  
The differences may be related to the type of 
treatment, e.g., surgery or androgen ablation 
(Leinonen et al., 2013). 
Breast cancer 
Disease 
Breast cancer is the most common cancer among 
women worldwide, accounting for 23% of all cases 
(Jemal et al., 2011). Although the prognosis has 
improved due to early diagnosis and therapies, breast 
cancer remains a major cause of death among 
women (14% of the cancer deaths). Most neoplasms 
of the breast originate from the ductal epithelium, 
while a minority originates from the lobular 
epithelium. A family history of breast cancer is 
associated with a 2-3-fold higher risk of the disease. 
Prognosis 
SPINK1 expression is associated with poor 
prognosis in estrogen receptor-positive breast cancer 
(Soon et al., 2011). 
Colorectal cancer 
Elevated serum SPINK1 has been observed in some 
patients with colorectal cancer. (Solakidi et al., 2004; 
Pasanen  et al., 1995) 
Disease 
Colorectal cancer is the third most commonly 
diagnosed cancer in males and the second in females 
(Jemal et al., 2011). It originates from colon or 
rectum, but, based on genetic studies, these are the 
same tumor. When locally confined, colorectal 
cancer is often curable by surgery. 
Prognosis 
High expression of SPINK1 has been associated 
with adverse prognosis and liver metastases (Gaber 
et al., 2010; Gaber at al., 2009) 
Bladder cancer 
Urinary SPINK1 is a useful marker for high-grade 
bladder cancer (Kelloniemi et al., 2003; Shariat et 
al., 2005; Gkialas et al., 2008, Patschan et al., 2012). 
Disease 
Bladder cancer is more common in males than in 
females and there is great geographic variation in 
incidence (Jemal et al., 2011). The highest incidence 
rates are found in Europe, North America and 
Northern Africa. Smoking, occupational exposures 
and chronic infection with Schistosoma hematobium 
are major risk factors. Most bladder cancers 
originate from the epithelial lining of the urinary 
bladder. Transitional cell carcinoma is the most 
common type of bladder cancer. 
Prognosis 
Serum SPINK1 has been shown to be an independent 
prognostic factor for bladder cancer (Kelloniemi et 
al., 2003) and for prediction of the response to 
chemotherapy (Pectasides et al., 1996). SPINK1 
expression is stronger in noninvasive than in 
invasive tumors and decreases with advancing tumor 
stage (Hotakainen et al., 2006; Patschan et al., 2012). 
Ovarian cancer 
The association of SPINK1 (TATI) and cancer was 
first observed in a patients with ovarian cancer 
(Stenman et al. 1982) 
Disease 
Ovarian cancer is the leading cause of death from 
gynecologic cancer. Most cases are diagnosed at 
advanced stages and, thus have relatively poor 
prognosis. The vast majority of ovarian cancers are 
epithelial. Cancer of the fallopian tubes is similar to 
ovarian cancer. 
Prognosis 
Increased SPINK1 expression is associated with 
adverse outcome in epithelial ovarian cancer 
(Huhtala et al., 1983; Paju et al., 2004). Elevated 
serum SPINK1 is an independent prognostic factor 
(Venesmaa et al., 1994; Venesmaa et al., 1998; Paju 
et al., 2004). 
Gastric cancer 
SPINK1 is detected in the normal gastric mucosa. 
Disease 
Gastric cancers account for 8% of all cancer cases 
and 10% of the deaths (Jamal et al., 2011). Over 70% 
of new cases and deaths occur in developing 
countries and rates are higher in males than in 
females.  
Helicobacter pylori infection is the main risk factor, 
but smoking also increases the risk of gastric cancer. 
Prognosis 
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The prognosis of gastric cancer is generally poor and 
metastases develop frequently. High tissue 
expression of SPINK1 is a sign of favorable outcome 
and loss of SPINK1 immunoreactivity in tumor 
tissue is associated with adverse prognosis (Wiksten 
et al., 2008). Serum SPINK1 is elevated in 50% of 
patients with gastric cancer (Solakidi et al., 2004). 
Renal cell carcinoma 
Disease 
Renal cancer comprises five distinct histological 
types. Within each type, there is considerable 
variation in clinical course and survival. Presently, 
many tumors are detected at an early stage by 
sonography performed for various reasons. 
Prognosis 
Prognosis of metastatatic and advanced disease is 
poor, but surgical treatment of localized disease is 
often curative. There are no specific serum markers 
for RCC. Elevated serum SPINK1 has been shown 
to be an independent prognostic factor in renal cell 
carcinoma (Meria et al., 1995; Paju et al., 2001). 
Pancreatitis, hereditary (Online 
Mendelian Inheritance in Man 
(OMIM): 167800) 
SPINK1 polymorphisms are found more frequently 
in patients with hereditary and idiopatic chronic 
pancreatitis (23%) than in healthy controls (0.4%) 
(Witt et al., 2000; Chen and Férec, 2009). Several 
mutations of SPINK1 cause loss-of-function by 
splicing, frameshift, deletion or initiation codon 
mutation. Some missense mutations have been 
suggested to affect polypeptide folding, leading to 
intracellular retention and degradation of the 
mutated polypeptide (Boulling et al., 2012). These 
mutations are suggested to cause pancreatitis 
because of SPINK1 deficiency. The most common 
mutation worldwide is a 101A>G transition within 
exon 3 resulting in the substitution of Asp by Ser at 
codon 34 (N34S) (Witt et al., 2000). The frequency 
of the N34S mutation in pancreatitis patients is 9-29 
% as compared to 0.5-2.5 % in the general 
population. In functional studies no differences in 
SPINK1 expression, trypsin inhibitory activity or 
binding to trypsin have been found between wild-
type and N34S-SPINK1. The mutations D50E, 
Y54H and R67C result in marked reduction or 
complete loss of SPINK1 secretion, and are 
classified as disease-causing mutations although 
trypsin inhibitory activity of the mutated proteins 
was retained (Király et al., 2007). The P55S 
mutation of SPINK1 is found in healthy controls as 
well as in pancreatitis patients with an incidence of 
0.5-1.3 % and 0.9-7 %, respectively (Witt et al., 
2000; Pfutzer et al., 2000). The role of this mutation 
in pancreatitis remains unclear. 
Disease 
Elevated serum and urine concentrations are caused 
by pancreatitis, i.e., inflammation of pancreas. Some 
hereditary mutations of the SPINK1 gene, increase 
the risk of pancreatitis. These cases are characterized 
by recurrent episodes of pancreatitis starting at 
young age. These episodes often lead to tissue 
damage and loss of pancreatic function, including 
insulin production. This also increases the risk of 
pancreatic cancer. 
Prognosis 
The life expectancy of the pancreatitis patients is 
close to normal. However, patients have an increased 
risk of developing pancreatic cancer (Weiss, 2014). 
Tropical calcific pancreatitis 
SPINK1 mutations, especially the N34S mutation 
has been reported to associate with tropical calcific 
pancreatitis (Bhatia et al., 2002). 
Disease 
Tropical calcific pancreatitis (OMIM: 608189) is a 
special type of chronic pancreatitis that occurs only 
in tropical countries. 
Prognosis 
Patients usually present at young age with recurrent 
abdominal pain and nutritional deficiencies. The 
disease often leads to beta-cell deficiency and 
diabetes requiring insulin before the age of 30. 
Prognosis is dismal and many patients succumb to 
complications caused by malnutrition. 
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